modelD01AE10

Diagram of D01AE10

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:EthylHydroxybenzoate
ATC code:D01AE10
route:oral
compartments:1
dosage:100mg
volume of distribution:0.5L
clearance:5L/h
other parameters in model implementation

Ethyl hydroxybenzoate, also known as ethylparaben, is a paraben-class preservative with antifungal and antibacterial properties, commonly used in cosmetics, pharmaceuticals, and food products to prevent microbial growth. It is sometimes used topically for dermatological applications due to its antifungal effects (ATC code D01AE10), but is not a primary therapeutic drug and is not approved for systemic use as a medicine.

Pharmacokinetics

No published pharmacokinetic studies in humans are available for ethyl hydroxybenzoate itself. The following parameters are broad estimates based on chemical similarity to other parabens (such as methylparaben and propylparaben) and limited reports of rapid absorption and elimination after oral or topical administration in animal models and indirect human exposure studies.

References

  1. Bury, D, et al., & Koch, HM (2019). Urinary metabolites of the UV filter 2-Ethylhexyl salicylate as biomarkers of exposure in humans. Toxicology letters 309 35–41. DOI:10.1016/j.toxlet.2019.04.001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30953687

  2. Yan, M, et al., & Zhu, YG (2010). Determination of metoclopramide in human plasma by LC-ESI-MS and its application to bioequivalance studies. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 878(11-12) 883–887. DOI:10.1016/j.jchromb.2010.02.006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20189472

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)